<DOC>
	<DOC>NCT02057380</DOC>
	<brief_summary>The purpose of this study is to provide access to continued treatment for subjects who participated in other Astellas sponsored trials and for whom the investigator feels the subject may benefit from continued treatment.</brief_summary>
	<brief_title>A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Subject must currently be participating in an Astellas sponsored linsitinib trial that has ended with respect to the overall study analysis. Subject must not have met criteria for discontinuation or have progressed on the current linsitinib study in which they are participating. Subject must be deriving benefit from continued treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Paclitaxel</keyword>
	<keyword>Linsitinib</keyword>
	<keyword>OSI-774</keyword>
	<keyword>Advanced Solid Tumor</keyword>
	<keyword>Tarceva</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>OSI-906</keyword>
</DOC>